{"slug":"skin","tag":"skin","variants":["skin"],"description":"No description yet","count":13,"kinds":{"cancer":6,"person":7},"related":[{"slug":"immunotherapy","tag":"immunotherapy","shared":6},{"slug":"trialist","tag":"trialist","shared":6},{"slug":"rare","tag":"rare","shared":2},{"slug":"eye","tag":"eye","shared":1},{"slug":"global","tag":"global","shared":1},{"slug":"guidelines","tag":"guidelines","shared":1},{"slug":"head-and-neck","tag":"head-and-neck","shared":1},{"slug":"melanoma","tag":"melanoma","shared":1},{"slug":"surgery","tag":"surgery","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1},{"slug":"viral","tag":"viral","shared":1}],"records":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","tldr":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","tldr":"Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma."},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","tldr":"Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines."},{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","tldr":"Houston dermatologist who led the trials that established cemiplimab, the first drug approved for advanced cutaneous squamous-cell carcinoma, and sonidegib for basal cell carcinoma."},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","tldr":"Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials."},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","tldr":"Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma."},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","tldr":"Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations."},{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","tldr":"Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer."},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","tldr":"Merkel cell carcinoma is a rare, fast-growing skin cancer, usually caused by a common virus (Merkel cell polyomavirus) or by sun damage. It was almost untreatable once it spread; PD-1/PD-L1 immunotherapy now gives lasting responses in about half of patients."},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","tldr":"Cutaneous squamous cell carcinoma is a sun-related skin cancer with over a million US cases a year, almost all cured by removing them. The 2 to 5% that grow deep or spread respond to PD-1 immunotherapy (cemiplimab, pembrolizumab), which is now also given after surgery in high-risk cases; transplant recipients cannot safely receive it."},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","tldr":"Basal cell carcinoma is a skin cancer and the most common cancer of all, caused by sun exposure and almost never life-threatening. Nearly all are removed surgically; the rare advanced cases are treated with drugs that block the hedgehog signalling pathway, and with immunotherapy if those fail."},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","tldr":"A melanoma inside the eye that is biologically unrelated to skin melanoma: different mutations, no response to standard immunotherapy, and a tendency to spread to the liver years later. Tebentafusp is the first drug ever to extend survival in the metastatic disease."},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","tldr":"Kaposi sarcoma is a blood-vessel cancer caused by the herpesvirus HHV-8, made famous by the AIDS epidemic. In people with HIV, antiretroviral therapy alone often shrinks it; liposomal doxorubicin or paclitaxel treat advanced disease, and it remains among the commonest cancers in sub-Saharan Africa, where paclitaxel is often unaffordable."}]}